Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Emory University

Neither a doctor nor a teaching hospital

Research payments

$20,918,642

2,490 payments

Through program year 2025, Emory University is reported as receiving $20,918,642 in research payments, across 2,490 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $406,774 89
2024 Research $950,757 195
2023 Research $2,284,779 591
2022 Research $4,110,680 402
2021 Research $3,802,252 257
2020 Research $5,018,309 430
2019 Research $4,345,090 526

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $10,877,810 828 payments
  2. Merck Sharp & Dohme Corporation $3,787,897 225 payments
  3. Medtronic Vascular, Inc. $855,422 81 payments
  4. Dexcom, Inc. $677,862 34 payments
  5. Biogen, Inc. $632,361 7 payments
  6. Inari Medical, Inc. $509,628 496 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $497,475 61 payments
  8. TG Therapeutics, Inc. $341,365 126 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $276,952 25 payments
  10. Medtronic USA, Inc. $267,803 47 payments
Studies the money was for Research payments · program years 2019–2025
  1. 214352 $4,975,255 34 payments
  2. 0000000000000000000000000000000000000000000000000000000000000000214352 $1,569,580 13 payments
  3. Study name not reported $967,441 11 payments
  4. A Phase I/II, Randomized, Open-Label Platform Study Utilizing A Master $849,205 155 payments
  5. Pilot Study of Pembrolizumab and Single-fraction, Low-dose, Radiation Therapy in Patients with Relapsed or Refractory Multiple Myeloma $837,838 4 payments
  6. A Phase I/II Open-Label, Dose Escalation Study to Explore Safety and C $639,692 144 payments
  7. Pilot Study of Pembrolizumab and Single-fraction, Low-dose, Radiation Therapy in Patients with Relapsed or Refractory Multiple Myeloma $453,090 1 payment
  8. A phase II study of docetaxel, ramucirumab, and pembrolizumab or patients with metastatic or recurrent NSCLC who progressed on platinum-doublet and PD-1,PD-L1 blockade $453,090 1 payment
  9. Pilot Study of Pembrolizumab and Stereotactic Radiation Surgery SRS for Patients with Melanoma or Non-Small Cell Lung Cancer NSCLC Brain Metastases BM $441,959 3 payments
  10. Master Protocol to Assess the Safety and Recommended Phase 2 Dose of N $369,629 134 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $430,147 58 payments
  2. Patient care $70,584 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record